CNTO 2476

Drug Profile

CNTO 2476

Alternative Names: CNTO-2476

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator Centocor
  • Developer Centocor Ortho Biotech; Janssen Biotech
  • Class Eye disorder therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Age-related macular degeneration
  • No development reported Retinitis pigmentosa

Most Recent Events

  • 06 Sep 2016 Janssen Pharmaceutical plans a phase II trial for Age-related macular degeneration (In adults, In the elderly) in Japan (Ophthalmic) (NCT02895815)
  • 01 Mar 2016 Phase-II clinical trials in Age-related macular degeneration in USA (Ophthalmic) (NCT02659098)
  • 22 Sep 2015 CNTO 2476 is still in phase I/II trials for Age-related macular degeneration in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top